nn
CJC-1295 & Ipamorelin in Los Angeles
CJC-1295 and ipamorelin are growth-hormone secretagogue compounds discussed in peptide clinics, but they should not be treated as routine anti-aging or body-composition medicines. A medical evaluation should start with the underlying symptoms and diagnosis.
Book an AppointmentDavid Nazarian, M.D. • Board Certified in Internal Medicine
What Are CJC-1295 and Ipamorelin?
CJC-1295
CJC-1295 is a synthetic growth-hormone-releasing hormone analog studied for its effects on growth-hormone signaling. Human clinical data remain limited, and it is not an FDA-approved anti-aging or body-composition treatment.
Ipamorelin
Ipamorelin is a growth-hormone secretagogue that acts through the ghrelin receptor pathway. It is not FDA-approved for anti-aging, muscle gain or routine wellness use.
Why regulatory status matters
FDA has identified potential safety concerns related to compounded ipamorelin and has described limited clinical data and safety concerns for CJC-1295. Product quality, purity and route of administration matter with peptide compounds.
Symptoms Deserve a Diagnosis First
Fatigue, poor sleep, reduced recovery, changes in body composition, low libido and reduced exercise performance are nonspecific symptoms. Thyroid disease, sleep disorders, anemia, medication effects, nutritional issues, testosterone or estrogen deficiency, metabolic disease and other conditions can produce similar complaints.
History & Medications
We review symptoms, goals, prescriptions, supplements, previous hormone or peptide use and relevant medical history.
Targeted Testing
Testing is selected based on the clinical question. It may include endocrine or metabolic assessment when appropriate rather than a one-size-fits-all panel.
Evidence-Based Options
We compare established treatments, expected benefits, uncertainty, risks and regulatory considerations before a treatment decision.
Potential Risks and Uncertainties
Growth-Hormone Pathway Effects
Compounds that stimulate GH signaling may affect glucose regulation, fluid balance, headaches, joint symptoms and other systems. Long-term safety for wellness or anti-aging use has not been established.
Compounded Peptide Quality
Peptide products can present challenges involving characterization, aggregation, impurities and immunogenicity. A compounded preparation is not the same as an FDA-approved finished drug product.
When Growth-Hormone Evaluation Is Appropriate
True growth-hormone disorders are evaluated in a defined endocrine context. A random growth-hormone level is generally not enough to diagnose deficiency because GH secretion is pulsatile. IGF-1 and, when indicated, formal endocrine testing may be part of the evaluation.
Learn about IGF-1 testing and therapy · Hormone testing · Peptide therapy overview
CJC-1295 & Ipamorelin FAQ
Are CJC-1295 and ipamorelin FDA-approved for anti-aging?
No. They should not be presented as FDA-approved anti-aging or body-composition therapies.
Do these peptides increase growth hormone?
They are designed to influence growth-hormone signaling, but a biological effect does not establish that a compound is appropriate, effective or safe for a specific wellness goal.
Should I have hormone testing first?
If symptoms could reflect an endocrine or metabolic condition, evaluation and targeted testing should come before choosing a peptide.
Can CJC-1295 and ipamorelin replace prescribed growth hormone?
No. Evaluation and treatment of a documented growth-hormone disorder is a separate medical process using established diagnostic criteria and approved therapies when indicated.
Start With a Physician-Led Evaluation
If you are considering CJC-1295, ipamorelin or another peptide, we can review the underlying concern, laboratory data, evidence, safety and established alternatives.
Book an Appointment
